Introduction – The objective of this article is to quantify venous thromboembolic events that occurred in France in 2022 and constituted the primary reason for hospitalization or admission to a medical ward, and to describe their hospital management as well as the diagnostic procedures performed. This overview is broken down by department and according to various sociodemographic indicators. Methods – Patients aged 18 years and older hospitalized for venous thromboembolism (VTE) in 2022 were identified using medical-administrative data, and analyses were stratified by type: pulmonary embolism (PE) and deep vein thrombosis (DVT). The prevalence of VTE as of January 1, 2023, was defined as the number of people alive on that date with a history of hospitalization for VTE or a history of long-term illness due to this condition (2012–2022). Standardized incidence and prevalence rates per 100,000 inhabitants were calculated using population data from French national statistics. Patients were followed for up to one year after hospitalization for VTE to determine survival (at six months and one year) and rates of drug treatment, particularly anticoagulants. Results – The prevalence of VTE among the adult population residing in France stood at 896,846 cases as of January 1, 2023. VTE was identified as the primary diagnosis for the entire hospital stay or for a specific medical unit in 62,055 patients hospitalized in 2022. While the age-standardized rate of hospitalized patients was overall 23% higher among men than among women, this disparity was greatest—with a ratio of nearly two to one—in the 45–64 age group. Significant disparities were found between departments, particularly in Martinique, which had the highest age-standardized rate in France. In general, the prevalence of health conditions and circumstances likely to have caused VTE was high, with nearly 30% having a history of cancer and 20% having had prolonged hospital stays in general medical wards in the preceding 3 months. The 1-year mortality rate following the acute event was approximately 20% for both PE and DVT, despite a rehospitalization rate for VTE of less than 5% for these conditions. Conclusion – Compared to epidemiological data on VTE from 2010, the rate of patients hospitalized for VTE was increasing in France. The high prevalence of a history of cancer among patients hospitalized for VTE partly explains the high 1-year mortality rate.